Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant

Summary

This is a perspective clinical study to assess the safety and efficacy of PD-1 inhibitors in patients with LT. Eligible patients have recurrent or metastatic cancer after LT, are not amenable to, or refractory after, locoregional therapy or to a curative treatment approach (eg, surgery, or ablation) and have previously been treated with sorafenib or other targeted therapy, either intolerant to this treatment or show radiographic progression after treatment. Biopsy is needed to exclude patients with positive allograft PD-L1 expression.

Timeline

Start

2019-05-01

Primary completion

2021-04-30

Completion

2022-10-31

Drugs

Indications